Vinay Prasad, chief of the FDA’s Center for Biologics Evaluation and Research, is planning to publish a paper this month to outline his office’s thinking of accelerating gene editing reviews.
A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.
Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...
Pairwise has licensed its Fulcrum® gene editing platform to the International Rice Research Institute (IRRI), a non-profit agricultural research organization. The agreement will enable IRRI to apply ...
Gene editing techniques, including CRISPR, prime editing, and nucleases, allow scientists to tackle genetic diseases, cancer, ...
Here’s the latest company planning for gene-edited babies The news: A West Coast biotech entrepreneur says he’s secured $30 million to form a public-benefit company to study how to safely create ...
DNA polymerases lie at the heart of diagnostic techniques like polymerase chain reaction (PCR), enabling early detection of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback